China Oncology ›› 2017, Vol. 27 ›› Issue (10): 833-838.doi: 10.19401/j.cnki.1007-3639.2017.10.012

Previous Articles     Next Articles

Research progress on circulating tumor biomarkers in prostate cancer

LI Gaoxiang, YANG Yunjie, DAI Bo   

  1. Department of Urology, Fudan University Shanghai Cancer Center, and Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
  • Online:2017-10-30 Published:2017-12-05
  • Contact: DAI Bo E-mail:

Abstract: Prostate cancer is one of the most common malignant tumors. Although (prostate-specific antigen, PSA) screening and multidisciplinary therapy had largely improved the therapy effects, new biological markers are needed to achieve individual treatment for prostate cancer. Circulating tumor biomarkers originate from primary tumor tissues and have close relationship with cancer metastases and prognosis. This review summarized the circulating tumor biomarkers detection methods and relevant clinical research in recent years.

Key words: Prostate cancer, Circulating tumor biomarkers, Detection, Individual treatment